VSIR and neoplasm: Targeting some of these immune checkpoints as VISTA, LAG-3, Tim-3, and TIGIT led to additive effects and reactivation of tumor-specific T cells58,60,61 and clinical trials are still ongoing (NCT04475523, NCT02812875, (NCT0348936962–66.